Amgen (AMGN) Getting Somewhat Positive Media Coverage, Analysis Shows
News articles about Amgen (NASDAQ:AMGN) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amgen earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 47.100965300696 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Analysts’ Recommendations for Celgene in August 2017 (finance.yahoo.com)
- Is There a Catalyst Out There For Amgen Inc. (NASDAQ:AMGN) – FLBC News (flbcnews.com)
- Amgen Inc. (AMGN) stock stream of 0.42% – Stocks Gallery (stocksgallery.com)
- Amgen Remains A Standout Among Biotechs (finance.yahoo.com)
- Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised (finance.yahoo.com)
Amgen (NASDAQ:AMGN) traded down 0.08% during mid-day trading on Wednesday, hitting $173.55. The stock had a trading volume of 1,972,231 shares. The firm has a market cap of $126.63 billion, a P/E ratio of 15.81 and a beta of 1.35. Amgen has a 12-month low of $133.64 and a 12-month high of $184.21. The stock has a 50-day moving average price of $173.87 and a 200 day moving average price of $166.86.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. Amgen’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.84 earnings per share. Equities analysts anticipate that Amgen will post $12.57 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be issued a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 annualized dividend and a yield of 2.65%. Amgen’s dividend payout ratio is presently 41.93%.
Several brokerages have weighed in on AMGN. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Deutsche Bank AG reissued a “hold” rating and issued a $174.00 price target (up previously from $172.00) on shares of Amgen in a report on Wednesday, July 26th. Cann reissued a “buy” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Finally, Cowen and Company reissued an “outperform” rating and issued a $209.00 price target on shares of Amgen in a report on Saturday, July 22nd. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.